A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for Prostate Cancer
Sites in Nashville, Memphis +48 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: Male·Age: 18+
Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025